Welcome to our dedicated page for HealWELL AI news (Ticker: HWAIF), a resource for investors and traders seeking the latest updates and insights on HealWELL AI stock.
HEALWELL AI Inc. develops and commercializes healthcare artificial intelligence software for preventative care, with a focus on clinical decision support, early disease identification, and workflow tools for healthcare providers. News about HWAIF commonly covers the company’s DARWEN™ AI platform, Smart Search, Smart Summary, Smart ID, and the use of AI-enriched clinical data to support real-world evidence across disease areas.
Company updates also include revenue and Adjusted EBITDA reporting, integration of Orion Health, enterprise health-system and Health Information Exchange software contracts, customer renewals, scientific publications, conference participation, and board or governance changes. HEALWELL trades on the Toronto Stock Exchange as AIDX and on the OTCQX market as HWAIF.
HEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF) has secured a $50 million credit agreement to support its acquisition of Orion Health. The credit facility, led by Scotiabank and RBC, includes a $20 million term loan and a $30 million revolving credit facility, with an additional uncommitted accordion feature of up to $25 million.
Combined with recent subscription receipt financings, HEALWELL has arranged over $100 million in total financing for the Orion Health acquisition. The company has initiated the pre-closing reorganization process by advancing NZD$5 million to the vendor, targeting a closing date of April 1, 2025.
Orion Health is a global Healthcare Intelligence Platform serving approximately 150 million lives across 11 countries. The acquisition will expand HEALWELL's footprint in preventative care and AI-driven healthcare solutions, particularly strengthening its presence in the public sector through Orion's government relationships.
HEALWELL AI (TSX: AIDX, OTCQX: HWAIF), a healthcare AI company specializing in preventative care, has announced its participation in two major upcoming investor conferences.
The company will first attend the 28th Annual Scotiabank TMT Conference on March 4-5, 2025, in Toronto. CEO Dr. Alexander Dobranowski will deliver a presentation on March 5 at 12:25 PM ET and participate in a keynote panel discussion titled 'AI and the Digital Health Ecosystem: Building a Smarter Future.'
Subsequently, HEALWELL will participate in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California. This event, one of North America's largest small-cap gatherings, will feature approximately 450 companies across various growth sectors. Dr. Dobranowski will conduct one-on-one meetings with investors to discuss HEALWELL's AI-powered healthcare solutions and preventative care vision.
HEALWELL AI (TSX: AIDX, OTCQX: HWAIF) has announced that its subsidiary VeroSource Solutions has launched new Digital Twin functionality on its VS Data-as-a-Service Platform. The technology creates a virtual representation of healthcare facilities, enabling real-time analysis and prediction without disrupting operations.
The Digital Twin system features seamless data integration of HL7 and ERP data, dynamic virtual modeling for real-time facility visualization, and enhanced decision-making capabilities. It incorporates population demographics, disease trends, and external factors to help healthcare professionals optimize operations, reduce costs, and improve patient care.
VeroSource's platform securely integrates health data from various sources including EMRs, pharmacies, and hospital information systems into a single platform. The infrastructure is fully compatible with HEALWELL's AI capabilities, allowing for expansion of digital co-pilot tools and data visualization across both companies' footprints.
HEALWELL AI's subsidiary Khure Health reported significant growth in Q4-2024, with its AI-Powered Physician Co-Pilots helping identify over 43,000 high-risk patients across 8 clinical specialties using 132 disease-specific algorithms. This represents a 22% quarter-over-quarter growth and 500% year-over-year growth compared to Q4-2023.
The company secured 4 new Master Services Agreements with pharmaceutical partners in Q4-2024, bringing the total to 16 MSAs, including partnerships with 7 of the world's 10 largest pharmaceutical companies. Khure's physician survey revealed an Net Promoter Score (NPS) of 84, with 82% of physicians confirming improved patient care through the AI technology.
HEALWELL has now onboarded over 800 physicians using its Khure Co-Pilots, with the WELL AI Decision Support (WAIDS) Program being the fastest-growing component, representing approximately 80% of new physician onboarding in Q4.
HEALWELL AI's subsidiary Pentavere has published a groundbreaking study in the Journal of Liquid Biopsy, demonstrating the effectiveness of their DARWEN™ AI platform in oncology care. The study, conducted with Princess Margaret Cancer Centre, shows the platform achieves a 100-fold improvement in processing time compared to manual methods when analyzing complex next-generation sequencing and liquid biopsy reports.
The research validates DARWEN™ AI as a leading clinical decision support tool for identifying actionable genomic alterations in lung cancer patients, enabling faster personalized treatment initiation. This is particularly significant as lung cancer is the second most common cancer and leading cause of cancer-related deaths worldwide. The study highlights how liquid biopsies, using blood tests instead of surgical procedures, can accelerate cancer treatment and personalized care.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) has received approval from New Zealand's Overseas Investment Office (OIO) to acquire Orion Health Holdings for NZD$175 million, with an additional performance-based earnout of up to NZD$25 million. The transaction is expected to close by April 1, 2025.
Orion Health, a global healthcare technology leader, serves over 70 customers across 11 countries with approximately 400 team members. The acquisition will expand HEALWELL's reach to over 150 million covered lives globally and strengthen its position in healthcare AI and preventative care. The company generates revenue through subscription licenses and services, primarily serving public sector clients with data interoperability and healthcare navigation solutions.
The merger aims to leverage synergies between both companies, focusing on AI-driven healthcare innovation and early disease detection. The OIO consent includes standard conditions for overseas acquisitions of New Zealand business assets, with a requirement to complete the acquisition by February 28, 2026.
HEALWELL AI (TSX: AIDX, OTCQX: HWAIF) announced a strategic cost optimization initiative expected to yield at least $3.0 million in annual savings. The restructuring includes headcount reductions, public company costs cuts, and decreased marketing expenses, preparing for the integration of its upcoming Orion Health acquisition.
The company received a $50 million credit facility commitment from a Schedule I Canadian bank for the Orion acquisition, expected to close by April 1, 2025. The acquisition will add approximately 400 employees and 11 global offices. HEALWELL expects minimal impact from potential U.S. tariffs, as it generates most revenues outside the U.S. and plans to expand AI product distribution through Orion's international network.
HEALWELL AI has completed the second tranche of its $55 million bought deal financing, issuing $30 million in convertible debenture subscription receipts. This follows the $25.5 million equity tranche completed last week. The funds will finance the acquisition of Orion Health Holdings
The company issued 30,000 debenture subscription receipts at $910 each, generating gross proceeds of $27.3 million. Each receipt converts to a $1,000 principal debenture with a 10% annual interest rate, maturing December 31, 2029. The debentures are convertible into Class A Subordinate Voting Shares at $2.40 per share.
The proceeds are held in escrow pending satisfaction of release conditions, primarily the completion of the Orion Health acquisition. If conditions aren't met by June 30, 2025, the funds will be returned to investors. The transaction received written approval from majority shareholders on January 27, 2025.
HEALWELL AI has completed the equity tranche of its upsized $55 million bought deal financing, raising gross proceeds of $25.5 million through the issuance of 12,737,500 subscription receipts at $2.00 per receipt. Each subscription receipt will convert into one Subordinate Voting Share and half a warrant, with whole warrants exercisable at $2.50 for 36 months.
The proceeds will fund the acquisition of Orion Health Holdings . The funds are held in escrow pending satisfaction of release conditions, primarily the completion of the Orion Health acquisition. The company expects to complete the convertible debenture portion of the financing around January 28, 2025.
Company insiders participated in the financing with 550,000 subscription receipts, representing approximately 4% of the equity tranche proceeds. If release conditions aren't met by June 30, 2025, the subscription receipts will be cancelled and funds returned to holders.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) has secured shareholder approval for its previously announced $55 million bought-deal financing and the acquisition of Orion Health Holdings . The approval was obtained through written consent from majority shareholders, eliminating the need for a special meeting.
A Schedule A Bank has granted internal risk approval for a $50 million senior secured credit facility, subject to finalizing a credit agreement. The facility will help fund the cash portion of the Orion acquisition.
The transaction involves issuing approximately 35.7 million Class A Subordinate Voting Shares at $1.61/share, totaling CA$57.4 million. The company expects to issue up to 14.7 million subscription receipts and 31,250 convertible debentures with a 10% annual interest rate. The transaction could result in issuing up to 76.4 million additional Subordinate Voting Shares at prices ranging from $1.61 to $2.50 per share.